This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-16 and is reviewed periodically as new material appears.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
=== GDP growth rate === In the first quarter of 2025, economic growth was a negative 0.5%. CBS News said the decline occurred because "businesses scrambled to bring in foreign goods ahead of new U.S. tariffs". Second quarter economic growth was 3.8% annualized (as if continuing for the full year). In the third quarter, real GDP grew to 4.3%, the fastest rate in two years.
=== Cytokines in differentiation === Activated naive CD4+ T cells differentiate into Th22 cells under the influence of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha). This process can be inhibited by the addition of increasing concentrations of transforming growth factor beta (TGF-beta). The combination of interleukin-21 (IL-21) and interleukin-23 (IL-23) can also induce the differentiation of naive T cells into Th22 cells via the endogenous toll-like receptor 4 ligand (TLR4), stimulating keratinocytes to secrete interleukin-23 (IL-23) and binds to the IL-23 receptor of skin dendritic cells. This mechanism induces the differentiation into Th22 cells and secretion of interleukin-22 (IL−22).
=== Aquaculture === Methylene blue is used in aquaculture and by tropical fish hobbyists as a treatment for fungal infections. With the help of light, it is also effective against bacteria and viruses. It can also be effective in treating fish infected with the parasitic protozoa Ichthyophthirius multifiliis (ich), although a combination of malachite green and formaldehyde is far more effective against it. Methylene blue also works against nitrite poisoning as it treats the resulting methemoglobinemia. Like in humans, it also treats cyanide poisoning. Non-professional sources also claim that it works for ammonia poisoning, but there is little medical literature to back this up. It is usually used to protect newly laid fish eggs from being infected by fungus. This is useful when the hobbyist wants to artificially hatch the fish eggs. For poisoning, injury (prevention of infection), or sickness, methylene blue is given as a "medicated bath" for the fish. Methylene blue is not without side effects to fish.
The history of smallpox extends into pre-history. Genetic evidence suggests that the smallpox virus emerged 3,000 to 4,000 years ago. Prior to that, similar ancestral viruses circulated, but possibly only in other mammals, and possibly with different symptoms. Only a few written reports dating from about 500–1000 CE are considered reliable historical descriptions of smallpox, so understanding of the disease prior to that has relied on genetics and archaeology. However, during the second millennium, especially starting in the 16th century, reliable written reports become more common. The earliest physical evidence of smallpox is found in the Egyptian mummies of people who died some 3,000 years ago. Smallpox has had a major impact on world history, not least because indigenous populations of regions where smallpox was non-native, such as the Americas and Australia, were rapidly and greatly reduced by smallpox (along with other introduced diseases) during periods of initial foreign contact, which helped pave the way for conquest and colonization. During the 18th century, the disease killed an estimated 400,000 Europeans each year, including five reigning monarchs, and was responsible for a third of all blindness. Between 20 and 60% of all those infected—and over 80% of infected children—died from the disease. During the 20th century, it is estimated that smallpox was responsible for 250–500 million deaths. In the early 1950s, an estimated 50 million cases of smallpox occurred in the world each year.
All four locations in the Los Angeles area are housed in historic buildings. Mel's Drive-In in the Sherman Oaks neighborhood of Los Angeles was built as Kerry's coffee shop in 1953. The googie style building was designed by Armet & Davis. Mel's Drive-In in West Hollywood was built as Ben Frank's in 1962. The googie style building was designed by Lane & Schlick. Mel's Drive-In in Hollywood is located in a portion of the former Max Factor makeup studio designed by theater architect S. Charles Lee. The Hollywood Regency style building was designed by S. Charles Lee and built in 1935. The Mel's Drive-In in Santa Monica was built as The Penguin in 1958. The googie style building was designed by Armet & Davis.
Sources: en.wikipedia.org
== History == Ketobemidone was first synthesized in 1942 by Eisleb and colleagues, at the laboratory of I.G. Farbenindustrie at Hoechst during the Second World War. The first study of it in humans was published in 1946, and it was introduced in clinical medicine shortly after. It was not in clinical use in the United States when the Controlled Substances Act 1970 was promulgated and was assigned to Schedule I with an ACSCN of 9628. As of 2013, no annual manufacturing quota was assigned by the DEA. Pfizer manufactures ketobemidone under the tradenames Ketogan and Ketorax. It is available as tablets, suppositories, and injection fluid. A sustained release formulation, sold as Ketodur, exists in some countries and contains 10 or 25 mg ketobemidone.
The α2 receptor couples to the Gi/o protein. It is a presynaptic receptor, causing negative feedback on, for example, norepinephrine (NE). When NE is released into the synapse, it feeds back on the α2 receptor, causing less NE release from the presynaptic neuron. This decreases the effect of NE. There are also α2 receptors on the nerve terminal membrane of the post-synaptic adrenergic neuron. Actions of the α2 receptor include: decreased insulin release from the pancreas increased glucagon release from the pancreas contraction of sphincters of the GI-tract negative feedback in the neuronal synapses - presynaptic inhibition of norepinephrine release in CNS increased platelet aggregation decreases peripheral vascular resistance α2 agonists (see actions above) can be used to treat: hypertension – decrease blood pressure-raising actions of the sympathetic nervous system α2 antagonists can be used to treat: impotence – relax penile smooth muscles and ease blood flow depression – enhance mood by increasing norepinephrine secretion Subtype unspecific β agonists can be used to treat:
year is the laboratory's determination of the age of the sample, in radiocarbon years range is the laboratory's estimate of the error in the age, at 1σ confidence. 'BP' stands for "before present", referring to a reference date of 1950, so that "500 BP" means the year AD 1450. For example, the uncalibrated date "UtC-2020: 3510 ± 60 BP" indicates that the sample was tested by the Utrecht van der Graaff Laboratorium ("UtC"), where it has a sample number of "2020", and that the uncalibrated age is 3510 years before present, ± 60 years. Related forms are sometimes used: for example, "2.3 ka BP" means 2,300 radiocarbon years before present (i.e. 350 BC), and "14C yr BP" might be used to distinguish the uncalibrated date from a date derived from another dating method such as thermoluminescence. Calibrated 14C dates are frequently reported as "cal BP", "cal BC", or "cal AD", again with 'BP' referring to the year 1950 as the zero date. Radiocarbon gives two options for reporting calibrated dates. A common format is "cal date-range confidence", where:
The development of insulin therapy has progressed significantly since the early 20th century, starting with animal-derived insulins. In 1922, Frederick Banting and Charles Best successfully used bovine insulin extract to treat humans for the first time. This breakthrough led to the commercial production of bovine insulin in 1923 by Eli Lilly and Company. That same year, Hans Christian Hagedorn founded the Nordisk Insulinlaboratorium in Denmark, which later became Novo Nordisk. In 1926, Nordisk received a Danish charter to produce insulin as a non-profit entity. In 1936, Canadian researchers D.M. Scott and A.M. Fisher developed a zinc insulin mixture, which was licensed to Novo. During this time, Hagedorn discovered that adding protamine to insulin could prolong its action, which led to the development of Neutral Protamine Hagedorn (NPH) insulin in 1946. NPH insulin was marketed by Nordisk in 1950. By 1953, Novo also developed Lente insulin by adding zinc to porcine and bovine insulins, resulting in a longer-acting form. A significant advancement in insulin production occurred in 1978 when Genentech developed the biosynthesis of recombinant human insulin using Escherichia coli bacteria and recombinant DNA technology. This allowed for the production of insulin identical to that produced by the human pancreas. In 1981, Novo Nordisk chemically and enzymatically converted porcine insulin into human insulin. Genentech's synthetic human insulin, produced in partnership with Eli Lilly, was approved by the U.S. Food and Drug Administration in 1982.
We won't see the rebirth of the Warsaw Pact and the Soviet Union." Chairman of the Islamic Committee of Russia Geydar Dzhemal stated that there was no difference between the Georgian-Ossetian conflict and the conflict in Chechnya. Former Prime Minister of Russia Mikhail Kasyanov stated in late September: "The trampling of the foundations of the Constitution of Russia leads to an aggressive foreign policy. A vivid example of this is the Russian-Georgian conflict. Instead of fulfilling the peacekeeping mandate, the Russian authorities gave the order to launch a full-scale war." Former Prime Minister of Estonia Mart Laar stated in late September 2008 that he personally saw that it was South Ossetia that attacked first when it began heavy shelling of the Georgian villages.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.